



Massachusetts General Hospital
Corporate & Foundation Relations
Office of Development

PRIVATE FUNDING OPPORTUNITIES: MAY 26, 2017

Please contact Corporate & Foundation Relations in the Office of Development at devcfr@mgh.harvard.edu if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than **15% in indirect costs (IDC)** will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

1. Joint Grant Awards Program (JGAP), American Academy of Family Physicians (AAFP)/American Academy of Family Physicians Foundation (AAFP Foundation)

This program supports research that have significant relevancy to Family Medicine. The program plays a major role in building research capacity by giving priority funding to new researchers or to those who mentor new investigators on the research team.

Award Amount: \$50,000 paid over 1-2 years

Indirect Costs: None

Proposal Deadline: Jul 7, 2017

Website: <http://www.aafpfoundation.org/foundation/our-work/grants-awards/all/joint-grant.html>

2. Research in Robotic Surgical Technology, American Society of Colon and Rectal Surgeons (ASCRS)/Research Foundation of ASCRS

The purpose of this program is to provide investigator the opportunity to pursue research interest, specifically germane to robotic surgical technology in the field of colon and rectal surgery. It is anticipated that successful research projects, initially funded through The Research Foundation of the ASCRS granting mechanism, will ultimately secure funding from other national funding agencies.

Award Amount: \$50,000 for 1 year

Indirect Costs: None

Application Deadline: Aug 15, 2017

Website: <https://www.fascrs.org/educational-grants-and-awards>



Do you want to learn more about identifying external funding opportunities? See [ECOR's website](#) for information on the funding opps database, **COS Pivot** or contact Amy Robb <arobb@mgh.harvard.edu> to schedule an individual consultation or group training session.

3. ADDF-AFTD Drug Discovery Grant - Accelerating Drug Discovery for Frontotemporal Degeneration, Association for Frontotemporal Degeneration (AFTD)

Research investigating the pathologic mechanisms underlying frontotemporal degeneration (FTD) is advancing, creating new targets for drug discovery. The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate and support innovative drug discovery programs for FTD through this Request for Proposals (RFP).

Priority areas for this program include:

- Development and testing of novel high throughput screening assays
- Identification and in vitro testing of potentially disease modifying compounds or biologics, including medicinal chemistry refinement, ADME, toxicology, pharmacokinetics, and pharmacodynamics studies.
- Testing of novel lead compounds, biologics, or repurposed drug candidates in a relevant animal model for preclinical proof of concept.
- Development and/or characterization of new model organisms or cellular models to support drug discovery efforts.

Award Amount: \$100,000-\$150,000 for 1 year

Indirect Costs: Unpublished

LOI Deadline: Jul 31, 2017

Website: <http://www.theaftd.org/research/funding-opportunities>

4. Beckman Young Investigators (BYI) Program, Arnold and Mabel Beckman Foundation

The Program is intended to provide research support to the most promising young faculty members in the early stages of academic careers in the chemical and life sciences particularly to foster the invention of methods, instruments and materials that will open up new avenues of research in science.

The Program provides research support to the most promising young faculty members in the early stages of their academic careers in the chemical and life sciences, particularly to foster the invention of methods, instruments and materials that will open up new avenues of research in science.

Award Amount: \$750,000 paid over 4 years

Indirect Costs: None

LOI Deadline: Aug 14, 2017

Website: <http://www.beckman-foundation.org/programs/beckman-young-investigators-program-information>

5. Macular Degeneration Research Standard Award, BrightFocus Foundation

The standard award provides significant funding for researchers who have already generated some amount of preliminary data, but are often required to demonstrate additional, significant progress before they can apply to governmental or industrial funding agencies.

Award Amount: \$160,000 paid over 2 years

Indirect Costs: None

LOI Deadline: Jul 11, 2017

Website: <http://www.brightfocus.org/grants/deadlines-guidelines>

6. Burroughs Wellcome Fund/ASTMH Postdoctoral Fellowship in Tropical Infectious Diseases, American Society of Tropical Medicine and Hygiene (ASTMH)

Established in 1999, the Fellowship supports career development of physician-scientists focused on infectious diseases of low and low-middle income countries. This unique fellowship provides funding for individuals to conduct research in tropical infectious diseases (and, on occasion, other clinical conditions unique to tropical medicine). It is designed to stimulate or sustain interest in research in tropical infectious diseases by individuals who are planning academic career paths focused on clinical research in order to build a long-term academic presence for the ASTMH's field in the USA and Canada.

Award Amount: \$130,000 paid over 2 years

Indirect Costs: None

Application Deadline: Jul 19, 2017

Website: <http://www.astmh.org/awards-fellowships-medals/astmh-sponsored-fellowships>

7. Children's Prize, Children's Prize Foundation

Child mortality is a core indicator for child health and well-being. Child survival remains an urgent concern. It is unacceptable that about 16,000 children still die every single day - equivalent to 11 deaths occurring every minute. The majority of these deaths can be attributed to treatable causes.

Infectious diseases (such as pneumonia and diarrhoea) and neonatal complications are responsible for the vast majority of under-five deaths globally. According to the latest estimates by WHO and the Maternal and Child Epidemiology Estimation Group, of the 5.9 million deaths in children under five that occurred in 2015, about half were caused by infectious diseases and conditions such as pneumonia, diarrhoea, malaria, meningitis, tetanus, HIV and measles.

The main killers of children under age five in 2015 included preterm birth complications (18%), pneumonia (16%), intrapartum-related complications (12%), diarrhoea (9%) and sepsis/ meningitis (9%). Importantly, almost half of all under-five deaths are attributable to

undernutrition, while more than 80 percent of neonatal deaths occur among newborn infants of low birth weight in the highest burden settings.

The Challenge

Propose a ready-to-execute project plan that is focused on saving children's lives under-five.

Projects are evaluated on their:

- ability to impact rates within a child mortality indicator (U5MR, IMR, NMR, etc.),
- effectiveness, innovation and scalability of the intervention approach within global health,
- feasibility of the proposed lives-saved estimate,
- probability of success, ease of verification, and
- inclusion of a process impact assessment.

To ensure that more children under the age of five survive and thrive, it is necessary to harness knowledge from around the world and across a broad range of disciplines to find the most effective solutions. Project proposals submitted may include, but are not limited to, intervention solutions in healthcare services, technology, education, infrastructure and agriculture.

Award Amount: \$250,000

Indirect Costs: 10%

Stage 1 Application Deadline: Jun 22, 2017

Website: <http://www.childrensprize.org/the-prize/>

8. Gilead Sciences Research Scholars Program in Pulmonary Arterial Hypertension (PAH), Gilead Sciences, Inc./Gilead Sciences Pty Ltd

The mission of the Gilead Sciences Research Scholars Program in Pulmonary Arterial Hypertension (PAH) is to support innovative scientific research that will advance knowledge in the field of pulmonary arterial hypertension, or PAH. Gilead Sciences, Inc. hopes that the research supported by these awards will enhance understanding of pulmonary arterial hypertension.

The Program is designed to support basic science and clinical research in the field of pulmonary arterial hypertension. Areas of research may include, but are not limited to:

- Basic science underlying PAH
- Genetics of PAH
- Pathophysiology of PAH
- Epidemiology of PAH
- Techniques for early diagnosis of PAH

The Program is designed to support new original research. Proposals with significant scientific overlap with funded research projects from a peer review agency or industry source will not be considered.

Award Amount: \$130,000 paid over 2 years

Indirect Costs: 10%

Application Deadline: Aug 4, 2017

Website: <http://researchscholarspah.gilead.com>

9. IOIBD Grants – Operating, International Organization For the Study of Inflammatory Bowel Disease (IOIBD)

The mission of the IOIBD is to promote the health of people with IBD worldwide by setting the direction for patient care, education and research.

A short presentation of the project outcome will be made during the next annual meeting by the sponsor.

Award Amount: Up to \$200,000 for 1 year. Preference will be given to grants less than or equal to \$50,000.

Indirect Costs: 10%

Application Deadline: Jun 30, 2017

Website: <http://www.ioibd.org/grants/>

10. Career Catalyst Research (CCR) Grants, Susan G. Komen

Career Catalyst Research (CCR) Grants are intended to foster promising breast cancer researchers who are in the early stages of their faculty careers by providing support for up to three years of "protected time" for research career development under the guidance of a Mentor Committee. It is expected that following the successful completion of a CCR Grant, awardees will launch independent research careers, successfully compete for subsequent research project funding, and emerge as key leaders in the fight against breast cancer.

The goal of the FY18 CCR Grant is to support outstanding translational research focused on those breast cancers that do not currently respond well to standard of care therapies including triple negative breast cancer (TNBC), ER+ breast cancer with acquired resistance, and metastatic breast cancer of all sub-types.

Letters of Intent addressing topics other than those described below will be administratively withdrawn from consideration without an opportunity for appeal.

1. New Treatments for Drug-Resistant Breast Cancers

The goal of this focus area is to support studies on new treatments for ER+ breast cancer and TNBC that have developed resistance to standard therapy, which will lead to a reduction in breast cancer deaths by 2026. Appropriate studies for this mechanism include, but are not limited to:

- The understanding of the mechanisms that contribute to acquired resistance in ER+ breast cancer and TNBC.
- Pre-clinical validation of novel molecular targets to overcome resistance to current therapies.
- Development of new therapies and/or new drug combinations, including new combinations of existing drugs.

*Proposals must focus directly on either ER+ breast cancer or TNBC. Proposals that address other tumor types, are broadly focused, or considered "hypothesis generating" are NOT appropriate for this Grant mechanism.

2. New Approaches to Combat Metastatic Breast Cancer

The goal of this focus area is to support translational research into the understanding and treatment of metastatic (Stage IV) breast cancer which will lead to a reduction in breast cancer deaths by 2026. Appropriate studies for this mechanism include, but are not limited to:

- Development of treatment strategies based on the mechanisms of metastatic growth and survival, incorporating the contribution of the tumor microenvironment to disease progression (including the immune system and potential vaccine strategies).
- New methods to treat metastatic disease, including novel, metastasis-specific therapeutic targets and improved delivery of therapies to metastases.
- Correlative studies of existing clinical trials for metastatic breast cancer, including analysis of biopsies and other patient samples. Such studies should leverage existing clinical trials to advance the understanding and treatment of metastatic breast cancer, including early molecular recurrence.

*Basic science studies focused on the mechanisms of breast cancer cell motility and broad exploratory studies are NOT appropriate for this Grant mechanism.

The Letter of intent must include a Research Plan and an Impact Statement. The Applicant/PI must propose a research plan that describes the research question and how the Research Project will lead to a reduction in breast cancer deaths by 2026. The Applicant/PI must specifically state how their proposal and specific aims will directly address the goals of the CCR research focus area, as stated above. The statement must also describe how this Research Project will lead to a reduction in breast cancer deaths by 2026.

Award Amount: \$450,000 paid over 3 years

Indirect Costs: 25%

LOI Deadline: Jun 7, 2017

Website: <http://ww5.komen.org/ResearchGrants/FundingOpportunities.html>

11. Independent Grants for Learning & Change: Request for Proposals (RFP) - Clinical Pathways in Breast Cancer, Pfizer, Inc. New

Pfizer Inc. and the National Comprehensive Cancer Network® (NCCN®) are collaborating to offer a new grant opportunity seeking proposals that use clinical care pathways to address a quality improvement initiative along the continuum of care for breast cancer patients. In the context of this RFP, a clinical pathway is defined as an evidence-based and systems-based standardization of a clinical process in order to support decision-making and improve the quality of breast cancer patient care.

Pfizer and NCCN recognize the emerging role of cancer care pathways as point of care informational tools used by health care providers with the potential to improve quality care based on the most current medical evidence and NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Supporting health care professionals in their use of clinical pathways is critical to improving patient care as clinicians face a variety of constraints on how they treat patients while payers and health care systems seek opportunities to improve cost effectiveness.

The mission of Pfizer Independent Grants for Learning & Change (IGLC) is to partner with the global health care community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

NCCN, a not-for-profit alliance of twenty-seven (27) leading cancer centers, is dedicated to improving the quality, effectiveness and efficiency of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. World renowned experts from NCCN Member Institutions, who diagnose and treat patients with a broad spectrum of cancers and are recognized for dealing with complex, aggressive, or rare cancers, are integral to the execution of this program.

This Request for Proposals (RFP) is being issued by both organizations. NCCN is the lead organization for review and evaluation of applications. A review committee, led by NCCN, will make decisions on which proposals will receive funding. Grant funding will be provided by Pfizer Inc. Collectively, \$2 million is available to fund several proposals.

The intent of the RFP is to encourage organizations to submit letters of intent (LOIs) describing concepts and ideas for developing, implementing and evaluating guideline-based clinical pathways in breast cancer.

NCCN and Pfizer encourage proposals using clinical pathways as decision support in order to improve clinical processes and improve the quality of breast cancer patient care. Proposals

should focus on quality improvement in all stages of breast cancer. They may be pilot projects or build on already existing pilot projects. Proposals that address the needs of underserved communities across the United States are especially encouraged.

Clinical pathways require evidentiary and operational processes, as well as measurement and reporting capabilities and/or strategies. They should be derived from a focus on high quality, cost-effective regimens, thereby limiting choices, but optimizing outcome for patients.

Proposals can address issues of appropriate and timely therapeutic interventions (i.e. medical, surgical, radiation oncology, and imaging), appropriate and timely diagnostic, molecular and pathologic evaluation, as well as appropriate and timely evaluation by integral specialties such as genetic counseling, fertility and reconstruction specialists. Additionally, proposals can address issues of compliance, adherence, toxicities, and survivorship.

All proposals funded must:

- Be based on guidelines (NCCN or other)
- Promote evidence-based care
- Be sustainable after the award funding is complete
- Collect data and report outcomes
- Have a goal to enhance clinical outcomes, patient satisfaction, or provider satisfaction
- Be flexible enough to address patient variability
- Promote administrative and system efficiency

Successful proposals will consider the overall efficiency of measurement and ways to incorporate measurement into care without increasing cost. Although proposals may include third party systems or other internal resources to promote guideline adherence, their overall cost to the system must be considered and reported.

Specific Areas of Interest:

1. Clinical Care Pathways Development
 - a. Develop and implement programs that improve efficiency and reduce costs to improve the quality of breast cancer patient care, including one or more of the following:
 - i. May be technology-based, but it is not necessary
 - ii. Support multidisciplinary collaboration
 - iii. Include partnerships to improve access to multidisciplinary and specialized care
 - iv. Improve patient adherence to medications and improve patient safety
 - v. Address patient emotional needs, psychosocial support and advocacy issues
 - vi. May incorporate virtual tumor boards, telemedicine, support services, etc.

- vii. May reduce payer administrative burden for authorization or payment of breast cancer patient care for providers

2. Clinical Care Pathways Implementation or Education

- a. Demonstration of care or process improvement in centers through the utilization of pathway programs
- b. Integration into electronic health records
- c. Implementation throughout healthcare system/affiliates
- d. Strategies for provider training and education

NCCN and Pfizer strongly encourage proposals that address the use of clinical pathways in community centers, low-resource centers, and centers that focus on the treatment of underserved of breast cancer patients. Proposals addressing under-represented populations as well as those from community settings are encouraged.

There are multiple project types that are eligible for funding through this RFP. Applicants should indicate which of the following best represents their project.

- Dissemination and Implementation (D&I) Research
- Quality Improvement
- Education or Educational research

Award Amount: \$250,000 paid over 2 years

Indirect Costs: 28%

LOI Deadline: Jun 26, 2017

Website: <http://www.pfizer.com/purpose/medical-grants/request-proposals>

12. Fellowships, Prevent Cancer Foundation

The Prevent Cancer Foundation is the only U.S. 501(c)3 nonprofit organization solely devoted to cancer prevention and early detection. Prevent Cancer focuses its resources on cancers that can be prevented through lifestyle changes or early detection, when treatment is more likely to be successful. Prevent Cancer is devoted to saving lives through cancer prevention and early detection across all populations. Since its founding in 1985, Prevent Cancer has invested more than \$138 million in research, education, advocacy and community outreach programs across the nation in support of its mission.

Applications must be written to indicate they are clearly within the scope of these priorities in order to be considered. Any applications that do not meet these qualifications will not be reviewed.

Fellowship proposals will be considered in the following categories:

- Basic, clinical, translational and population-based research projects
- Education programs in cancer prevention

- Early detection projects
- Behavioral intervention projects

Examples of acceptable proposals:

- Projects that are clearly in the field of cancer prevention or early detection
- Research projects which, if successful, may lead directly to reducing the incidence of cancer *
- Primary and secondary prevention research on all types of cancers
- Creative or innovative approaches to cancer prevention research

* Examples of such projects include, but are not limited to: research that leads to improvement in early detection and intervention, research into dietary links to cancer, behavioral/educational aspects of cancer prevention, epidemiological and genetic studies that may have a direct impact on cancer prevention, and primary prevention programs that focus on children and adolescents.

Proposals must fall within the scope of the Foundation's mission and funding priorities to be considered. The goal of the Foundation's research program is to provide funding for innovative projects expected to lead to future funding from other peer-reviewed sources.

Basic science grants must demonstrate substantial potential for impact on prevention or early detection of cancer (specifically, pre-clinical research is acceptable but must be prevention-oriented and clearly identifiable as translational).

Educational Environment and Course Requirements:

The Prevent Cancer Foundation provides funds to create an environment in which young investigators who wish to pursue a career in cancer prevention will be optimally trained. Fellowship applicants should outline how their educational environment will contribute to their career development as a cancer prevention researcher. Refer to "Overview of Research Proposal" for additional guidance. A discussion of the educational environment should be addressed in the "Statement of Significance" section of the research plan.

To ensure adequate exposure in the discipline, the Foundation's minimal requirement is that its fellows take one to two courses per year (for a grade) in an area in which the candidate has not received prior training. Course fees may be included in the budget. However, preference is given to applicants whose course fees are covered by their institutions.

Courses may be taken in the following areas: Biostatistics; Epidemiology; Health Behavior/Health Education; Health Services Research; Nutritional Science; and Behavioral Sciences. The names of these courses, their location and a timeline for completing them must be included in the fellowship application. A discussion of how the applicant will meet the educational course requirement should be addressed in the "Evaluation" section of the research plan.

Award Amount: \$100,000 paid over 2 years

Indirect Costs: None

Application Deadline: Jun 29, 2017

Website: <http://preventcancer.org/our-work/grants-fellowships/>

13. Grants, Prevent Cancer Foundation

The Prevent Cancer Foundation is the only U.S. 501(c)3 nonprofit organization solely devoted to cancer prevention and early detection. Prevent Cancer focuses its resources on cancers that can be prevented through lifestyle changes or early detection, when treatment is more likely to be successful. Prevent Cancer is devoted to saving lives through cancer prevention and early detection across all populations. Since its founding in 1985, Prevent Cancer has invested more than \$138 million in research, education, advocacy and community outreach programs across the nation in support of its mission.

Research must be conducted in the United States primarily.

Applications must be written to indicate they are clearly within the scope of these priorities in order to be considered. Any applications that do not meet these qualifications will not be reviewed.

Grant proposals will be considered in the following categories:

- Basic, clinical, translational and population-based research projects
- Education programs in cancer prevention
- Early detection projects
- Behavioral intervention projects

Examples of acceptable proposals:

- Research projects which, if successful, may lead directly to reducing the incidence of cancer *
- Primary and secondary prevention research on all types of cancers
- Creative or innovative approaches to cancer prevention research

* Examples of such projects include, but are not limited to: research that leads to improvement in early detection and intervention, research into dietary links to cancer, behavioral/educational aspects of cancer prevention, epidemiological and genetic studies that may have a direct impact on cancer prevention, and primary prevention programs that focus on children and adolescents.

Proposals must fall within the scope of the Foundation's mission and funding priorities to be considered. The goal of the Foundation's research program is to provide funding for innovative projects expected to lead to future funding from other peer-reviewed sources.

Basic science grants must demonstrate substantial potential for impact on cancer prevention or early detection (specifically, pre-clinical research is acceptable but must be prevention-oriented and clearly identifiable as translational).

Studies related to therapy for established or advanced cancer will not be reviewed.

Award Amount: \$100,000 paid over 2 years

Indirect Costs: None

Application Deadline: Jun 29, 2017

Website: <http://preventcancer.org/our-work/grants-fellowships/>

14. HTRS Mentored Research Award (MRA) Program, Thrombosis & Hemostasis Societies of North America

The HTRS Mentored Research Award (MRA) Program provides financial support for qualified fellows or junior attending/junior faculty pursuing clinical, translational, or basic science research projects in hemostasis and/or thrombosis under the guidance of an experienced mentor.

Award Amount: \$162,000 paid over 2 years

Indirect Costs: 8%

Preliminary Proposal Deadline: Jul 21, 2017

Website: <http://www.htrs.org/HTRS/Grants-Awards/Mentored-Research-Awards>

15. THSNA Mentored Research Award, Thrombosis & Hemostasis Societies of North America

The Thrombosis and Hemostasis Societies of North America (THSNA) Mentored Research Award (MRA) provides financial support for a clinical or basic science research project in hemostasis and/or thrombosis under the guidance of an experienced mentor. The goal of this award is to mentor professionals in the early stages of their research career in hemostasis and/or thrombosis in order to encourage them to continue working in benign hematology.

Eligible research projects in hemostasis and/or thrombosis include:

- Clinical projects related to one of the sub-disciplines of THSNA (hematology, science of hemostasis and/or thrombosis, laboratory medicine, obstetrics and gynecology, nursing, pharmacy and pharmacology, and coagulation laboratory technology), including, for example, epidemiological or translational studies, with or without a secondary component of laboratory work OR
- Basic science/laboratory projects related to one of the same sub-disciplines of THSNA, including, for example, molecular biology, physiology, pharmacology, or translational studies where the primary emphasis is laboratory work, with or without a secondary component of clinical work.

Award Amount: \$162,000 paid over 2 years

Indirect Costs: 8%

Preliminary Proposal Deadline: Jul 21, 2017

Website: <http://www.htrs.org/HTRS/Grants-Awards/Mentored-Research-Awards/>

16. Positive Action Challenges (PAC), ViiV Healthcare

Positive Action Challenges is dedicated to solving the big problems in HIV that limit health, opportunity and rights.

ViiV Healthcare runs challenge prizes connecting experts in HIV and international development communities with solvers and innovators from other fields. Our challenges aim to identify innovative solutions that can overcome the common bottlenecks faced in tackling HIV.

Healthcare development experts and innovators inspired to apply their skills and ideas can play a valuable part in solving the enduring problems in HIV.

Current Challenges

- Improving Retention of Breastfeeding Women LWHIV on ART

This challenge is seeking to Identify effective solutions at the community level to improve retention of mothers living with HIV on ART through pregnancy, delivery, breastfeeding and beyond to prevent mother-to-child transmission of HIV. The prize amount is up to £80,000.

Award Amount: Up to \$100,000. Challenges offer two types of prize:

- Incubation prize. Incubation prizes encourage untested ideas to be piloted to obtain proof of concept data before scale-up or wider implementation is possible for the idea.
- Grand prize. Grand prizes award fully-formed innovations (with proof of concept, data and/or field testing) to allow immediate implementation, up-take and scale-up.

Indirect Costs: Unpublished

Concept Paper Deadline: Jun 30, 2017

Website: <https://positiveactionchallenges.com/>